Oura 2026: Ring 5 Launches Blood Pressure Tracking Under FDA Carve-Out
Oura debuted its Ring 5 on May 28 with cuffless blood pressure monitoring, exploiting an FDA wellness carve-out finalized in January. The launch — alongside Samsung's US rollout and a reported $11 billion IPO filing — marks the first major commercial test of deregulated consumer health tech.
Dr. Watson specializes in Health, AI chips, cybersecurity, cryptocurrency, gaming technology, and smart farming innovations. Technical expert in emerging tech sectors.
LONDON, Thursday, June 4, 2026 — Oura launched its Ring 5 on May 28 with cuffless blood pressure tracking, becoming the first major wearables maker to commercialize a clinical-adjacent vital sign under the FDA's January wellness deregulation. Oura officially launched its Ring 5 on May 28, 2026, claiming the title of the world's smallest smart ring, while Samsung has yet to announce a follow-up to its Galaxy Ring nearly two years after its debut. The device starts at $349 and arrives weeks after Oura filed for an IPO at an $11 billion valuation, with the smart ring market projected to grow from $518.9 million in 2026 to $3.77 billion by 2034. CEO Tom Hale has projected close to $2 billion in 2026 sales, with paid membership on track to surpass five million users this quarter. Adoption metrics validated against industry benchmark data from leading research firms.
Key Takeaways
- Oura's Ring 5 introduces "Blood Pressure Signals," a wellness-classified feature that estimates overnight blood pressure trends without FDA clearance.
- The launch operationalizes FDA guidance issued Jan. 6, 2026 that allows sensors to "estimate, infer, or output" blood pressure for wellness uses without premarket review.
- Samsung beat Oura to US shelves with a Galaxy Watch blood pressure feature on March 31, also classified as wellness-only.
- STAT and the Boston Globe report clinicians warning that cuffless PPG-based estimates lack a finalized ISO validation protocol.
- Oura is targeting an IPO around an $11 billion valuation against forecast 2026 revenue near $2 billion.
Context & Analysis
The regulatory pivot dates to January. The U.S. Food and Drug Administration published guidance on Jan. 6, 2026, that reduces oversight of certain digital health products, including AI-enabled software and wearable devices. Then-Commissioner Marty Makary framed the shift as competitive necessity. Makary announced that wearable devices providing non-medical-grade information will not be subject to FDA regulation, telling "Varney & Co." that companies can release devices or software simply providing information without FDA regulation — the only stipulation being claims of medical-grade or clinical-grade measurement.
Oura moved first internally. Smart ring maker Oura swiftly planted the pivot foot, with chief medical officer Ricky Bloomfield telling STAT the company started conversations with its product team the same day the guidance came out about what its roadmap looks like and features it could ship sooner. Samsung followed in March. Samsung officially launched its blood pressure monitoring feature for Galaxy Watch users in the United States starting March 31, 2026, allowing selected users to check and track their blood pressure directly from their wrist using a Galaxy Watch and the Samsung Health Monitor app.
Related: Why Regulated Industries Are Scaling Health Tech in 2026, Led by Microsoft, Amazon and Google
| Company | Position | Recent Move | Source |
|---|---|---|---|
| Oura | Smart ring leader | Ring 5 with blood pressure signals, May 28 | MedTech Dive |
| Samsung | Galaxy Watch incumbent | US BP rollout March 31, 2026 | Android Authority |
| FDA | Regulator | General Wellness guidance revised Jan. 6 | Fox Business |
| RingConn | Low-cost challenger | Gen 3 ships with BP risk flag, Jan. 2026 | Cardilog |
Competitive Landscape
The Ring 5 launches into a category Oura is consolidating through both product and litigation. With Oura pushing ahead on health innovation and Samsung reportedly delaying the Galaxy Ring 2 until early 2027, the gap between the two biggest names in the smart ring category is widening fast. The headline software feature is Health Radar. Blood Pressure Signals tracks nighttime blood pressure patterns by analyzing changes in blood flow and vessel behavior during sleep, and while not a replacement for a clinical arm cuff, it can flag early cardiovascular risk indicators that daytime readings often miss. The development follows concerns raised by major industry analysts this quarter. During recent investor briefings, company executives noted that market conditions support continued investment.
Related: Microsoft, Google, Oracle Strengthen Health Tech Interoperability
Patent enforcement is reshaping the field. In November 2025, Oura filed an ITC complaint against Samsung, Reebok, Zepp Health, and Nexxbase, having already secured import bans against competitors Ultrahuman and RingConn through similar complaints. Pricing splits the market. The no-subscription model remains Samsung's biggest competitive edge — while Oura charges $5.99/month for full functionality, the Galaxy Ring includes everything for its $399 purchase price.
| Company | Category | Key Development | Impact |
|---|---|---|---|
| Oura | Smart ring | Ring 5 + IPO filing at $11B valuation | Category benchmark |
| Samsung | Smartwatch | Galaxy Watch BP live in US | Distribution scale |
| Whoop | Fitness band | Cuffless BP estimate via PPG | Subscription model |
| RingConn | Smart ring | Gen 3 BP risk flag, no subscription | Price disruption |
Additional coverage: Siemens Healthineers and GE HealthCare Advance AI Imaging Adoption
For deeper context, see our Health Tech analysis: "XCaliber Health $6.5M Seed 2026: ManchesterStory Backs Healthcare AI".
What It Means
For Enterprise Buyers
Self-insured employers and health plans evaluating wearable programs face a sharper diligence question. Products from Whoop, Oura, Samsung, and others do not directly measure blood pressure and instead estimate it by analyzing data collected by a wearable's photoplethysmography sensor, which measures the pulsing volume changes in arteries as blood circulates. Validation transparency remains thin. Despite FDA's nudging, companies have disclosed little about how their devices were validated and how well they work — Oura has promised to publish more information about its blood pressure features in early June, while a Samsung spokesperson shared that the company used an ISO standard for cuffed devices but did not offer data about the performance of its blood pressure product.
For Investors
Oura's IPO becomes the cleanest test of whether deregulated consumer health tech commands software-like multiples. The $11 billion target prices the company at roughly five times forecast 2026 revenue. Oura filed for IPO amid healthcare push in May 2026. Capital is already concentrating around platforms with consumer scale and clinical adjacency.
Additional coverage: What Health Systems Prioritize in 2026, According to SAP, Philips and Deloitte
For deeper context, see our related analysis: "AWS, Google Cloud, Microsoft Compete for Health Tech Workloads".
Forward Outlook
Oura has committed to publishing validation data on its blood pressure features in early June, the first real disclosure test of the wellness pathway. The company is separately pursuing FDA clearance for hypertension detection — a medical-grade claim — on a longer timeline. The new wellness tool would alert users to signs of increasing blood pressure, while Oura is studying a separate feature to flag hypertension that would go through the Food and Drug Administration. An ISO standard for cuffless blood pressure validation, still in draft, would set the next regulatory inflection point.
Related: What Health Tech Buyers Want in 2026, According to Microsoft, Google and Gartner
Related: After Years of Fragmentation, Health Tech Consolidates Around AI in 2026
FAQ
For broader market context: SAP, ServiceNow, GE HealthCare Expand Health Tech Platforms for Enterprises
And on platform competition: Epic Systems, Oracle & Microsoft Advance Health Tech Interop in 2026
Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.
Related Coverage
About the Author
Dr. Emily Watson
AI Platforms, Hardware & Security Analyst
Dr. Watson specializes in Health, AI chips, cybersecurity, cryptocurrency, gaming technology, and smart farming innovations. Technical expert in emerging tech sectors.
Frequently Asked Questions
What did Oura launch on May 28, 2026?
Oura unveiled the Ring 5, its fifth-generation smart ring, alongside a new Health Radar feature that includes Blood Pressure Signals for tracking overnight blood pressure trends and a 30-day nighttime breathing analysis. The device starts at $349 and is positioned as a wellness product, not an FDA-cleared medical device.
Why doesn't the Ring 5's blood pressure feature need FDA clearance?
On January 6, 2026, the FDA revised its General Wellness guidance to allow wearables that estimate blood pressure via sensors like photoplethysmography to qualify as low-risk wellness products, provided they don't make diagnostic claims about conditions such as hypertension. Oura and Samsung both market their blood pressure features under this carve-out.
How does this compare to Samsung's Galaxy Watch blood pressure feature?
Samsung began rolling out blood pressure monitoring to US Galaxy Watch users on March 31, 2026, also positioned as a wellness feature outside FDA clearance. Samsung uses a modified ISO protocol designed for cuffed devices, while no finalized ISO standard exists yet for cuffless wearable blood pressure validation.
What are clinicians' concerns about these devices?
Experts cited by STAT and the Boston Globe warn that cuffless PPG-based blood pressure estimates are unreliable, that validation data has been sparsely disclosed by manufacturers, and that consumers may delay seeking medical care if wellness devices give them false reassurance about elevated readings.
What is Oura's IPO situation?
Oura filed for an IPO in May 2026 reportedly targeting an $11 billion valuation, with CEO Tom Hale projecting close to $2 billion in 2026 sales and paid membership on track to exceed five million users in the current quarter.
